{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Mutation-Related+Cancer&page=2",
    "query": {
      "condition": "Gene Mutation-Related Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Mutation-Related+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T16:12:08.336Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03424213",
      "title": "Race-related Alternative Splicing: Novel Targets in Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "No interventions - retrospective data collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 169,
      "start_date": "2018-01-30",
      "completion_date": "2021-07-14",
      "has_results": false,
      "last_update_posted_date": "2022-02-02",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03424213"
    },
    {
      "nct_id": "NCT01904136",
      "title": "Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia With Gene Mutations",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Therapy-Related Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Natural Killer Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2014-04-22",
      "completion_date": "2022-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904136"
    },
    {
      "nct_id": "NCT03904134",
      "title": "Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Myelodysplastic Syndromes",
        "Non-hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Acquired Aplastic Anemia",
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Donor Search Prognosis Score",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1753,
      "start_date": "2019-06-14",
      "completion_date": "2025-01-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 52,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904134"
    },
    {
      "nct_id": "NCT05514496",
      "title": "A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "NX-019",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nalo Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2022-10-05",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514496"
    },
    {
      "nct_id": "NCT03190174",
      "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "PEComa",
        "Epithelioid Sarcoma",
        "Desmoid Tumor",
        "Chordoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Classical Hodgkin Lymphoma",
        "Colorectal Cancer",
        "MTOR Activating Mutation"
      ],
      "interventions": [
        {
          "name": "Nab-Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sarcoma Oncology Research Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-08-24",
      "completion_date": "2021-12-02",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190174"
    },
    {
      "nct_id": "NCT03330847",
      "title": "To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib Continuous (28-Day cycle) 300 mg BD.",
          "type": "DRUG"
        },
        {
          "name": "Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).",
          "type": "DRUG"
        },
        {
          "name": "Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 273,
      "start_date": "2018-03-07",
      "completion_date": "2026-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330847"
    },
    {
      "nct_id": "NCT01238250",
      "title": "Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "16P11.2 Deletion Syndrome",
        "16p11.2 Duplications",
        "1Q21.1 Deletion",
        "1Q21.1 Microduplication Syndrome (Disorder)",
        "ACTL6B",
        "ADNP",
        "AHDC1",
        "ANK2",
        "ANKRD11",
        "ARID1B",
        "ASH1L",
        "BCL11A",
        "CHAMP1",
        "CHD2",
        "CHD8",
        "CSNK2A1",
        "CTBP1",
        "CTNNB1 Gene Mutation",
        "CUL3",
        "DDX3X",
        "DNMT3A",
        "DSCAM",
        "DYRK1A",
        "FOXP1",
        "GRIN2A",
        "GRIN2B",
        "HIVEP2-Related Intellectual Disability",
        "HNRNPH2",
        "KATNAL2",
        "KDM5B",
        "KDM6B",
        "KMT2C Gene Mutation",
        "KMT2E",
        "KMT5B",
        "MBD5",
        "MED13L",
        "PACS1",
        "PPP2R5D-Related Intellectual Disability",
        "PTCHD1",
        "REST",
        "SCN2A Encephalopathy",
        "SETBP1 Gene Mutation",
        "SETD5",
        "SMARCA4 Gene Mutation",
        "SMARCC2",
        "STXBP1 Encephalopathy With Epilepsy",
        "SYNGAP1-Related Intellectual Disability",
        "TBR1",
        "ARHGEF9",
        "HNRNPU",
        "PPP3CA",
        "PPP2R1A",
        "SLC6A1",
        "2p16.3 Deletions",
        "5q35 Deletions",
        "5q35 Duplications",
        "7q11.23 Duplications",
        "15Q13.3 Deletion Syndrome",
        "16p11.2 Triplications",
        "16P12.2 Microdeletion",
        "16P13.11 Microdeletion Syndrome (Disorder)",
        "17Q12 Microdeletion Syndrome (Disorder)",
        "17Q12 Duplication Syndrome",
        "17Q21.31 Deletion Syndrome",
        "17q21.3 Duplications",
        "ACTB",
        "ADSL",
        "AFF2",
        "ALDH5A1",
        "ANK3",
        "ARX",
        "ATRX Gene Mutation",
        "AUTS2 Syndrome",
        "BCKDK",
        "BRSK2",
        "CACNA1C",
        "CAPRIN1",
        "CASK",
        "CASZ1",
        "CHD3",
        "CIC",
        "CNOT3",
        "CREBBP Gene Mutation",
        "CSDE1",
        "CTCF",
        "DEAF1",
        "DHCR7",
        "DLG4",
        "EBF3",
        "EHMT1",
        "EP300 Gene Mutation",
        "GIGYF1",
        "GRIN1",
        "GRIN2D",
        "IQSEC2-Related Syndromic Intellectual Disability",
        "IRF2BPL",
        "KANSL1",
        "KCNB1",
        "KDM3B",
        "NEXMIF",
        "KMT2A",
        "MBOAT7",
        "MEIS2",
        "MYT1L",
        "NAA15",
        "NBEA",
        "NCKAP1",
        "NIPBL",
        "NLGN2",
        "NLGN3",
        "NLGN4X",
        "NR4A2",
        "NRXN1",
        "NRXN2",
        "NSD1 Gene Mutation",
        "PHF21A",
        "PHF3",
        "PHIP",
        "POMGNT1",
        "PSMD12",
        "RELN",
        "RERE",
        "RFX3",
        "RIMS1",
        "RORB",
        "SCN1A",
        "SETD2 Gene Mutation",
        "SHANK2",
        "SIN3A",
        "SLC9A6",
        "SON",
        "SOX5",
        "SPAST",
        "SRCAP",
        "TAOK1",
        "TANC2",
        "TCF20",
        "TLK2",
        "TRIO",
        "TRIP12",
        "UPF3B",
        "USP9X",
        "VPS13B",
        "WAC",
        "WDFY3",
        "ZBTB20",
        "ZNF292",
        "ZNF462",
        "2Q37 Deletion Syndrome",
        "9q34 Duplications",
        "15q15 Deletions",
        "15Q24 Deletion",
        "NR3C2",
        "SYNCRIP",
        "2q34 Duplication",
        "2q37.3 Deletion",
        "6q16 Deletion",
        "15q11.2 BP1-BP2 Deletion",
        "16p13.3 Deletion",
        "17Q11.2 Microduplication Syndrome (Disorder)",
        "17p13.3",
        "Xq28 Duplication",
        "CLCN4",
        "CSNK2B",
        "DYNC1H1",
        "EIF3F",
        "GNB1",
        "MED13",
        "MEF2C",
        "RALGAPB",
        "SCN1B",
        "YY1",
        "Xp11.22 Duplication",
        "PACS2",
        "MAOA",
        "MAOB",
        "HNRNPC",
        "HNRNPD",
        "HNRNPK",
        "HNRNPR",
        "HNRNPUL2",
        "5P Deletion Syndrome",
        "TCF7L2 Gene Mutation",
        "HECW2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Simons Searchlight",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100000,
      "start_date": "2010-10",
      "completion_date": "2050-10",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Lewisburg, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lewisburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01238250"
    },
    {
      "nct_id": "NCT02091141",
      "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Solid Tumors",
        "Biliary Cancer",
        "Salivary Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 673,
      "start_date": "2014-04-14",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 60,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02091141"
    },
    {
      "nct_id": "NCT05498389",
      "title": "EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "EGFR Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "EMB-01",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2023-06",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 2,
      "location_summary": "Orange, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498389"
    },
    {
      "nct_id": "NCT05370469",
      "title": "Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer",
        "EGFR Gene Mutation",
        "EGFR",
        "ALK Gene Mutation",
        "RET Gene Mutation",
        "MET Gene Mutation",
        "KRAS Mutation-Related Tumors",
        "BRAF",
        "ROS1 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Sensus Smartwatch Application",
          "type": "OTHER"
        },
        {
          "name": "RX Cap",
          "type": "DEVICE"
        },
        {
          "name": "Fitbit Sense",
          "type": "DEVICE"
        },
        {
          "name": "Surveys",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-08-25",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-06-27T16:12:08.336Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05370469"
    }
  ]
}